QUADRAMET Drug Patent Profile

Which patents cover Quadramet, and when can generic versions of Quadramet launch?

Quadramet is a drug marketed by Lantheus Medical and is included in one NDA.

The generic ingredient in QUADRAMET is samarium sm-153 lexidronam pentasodium. Additional details are available on the samarium sm-153 lexidronam pentasodium profile page.

Summary for QUADRAMET

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for QUADRAMET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lantheus Medical	QUADRAMET	samarium sm-153 lexidronam pentasodium	INJECTABLE;INJECTION	020570-001	Mar 28, 1997		DISCN	Yes	No

International Patents for QUADRAMET

See the table below for patents covering QUADRAMET around the world.

Country	Patent Number	Title	Estimated Expiration
South Africa	8502799
Brazil	8907255
Slovakia	279107
European Patent Office	0411941	Procédé de purification d'acides aminométhylènephosphoniques (Process for purifying aminomethylenephosphonic acids)
Canada	2020950	METHODE DE PURIFICATION D'ACIDES AMINOMETHYLENEPHOSPHONIQUES (PROCESS FOR PURIFYING AMINOMETHYLENEPHOSPHONIC ACIDS)

Supplementary Protection Certificates for QUADRAMET

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0164843	C980021	Netherlands		PRODUCT NAME: SAMARIUM[153 SM] LEXIDRONAM, DESGEWENST IN DE VORM VAN EEN FYSI OLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET PENTANATRIUMZO UT; NAT.REGISTRATION NO/DATE: C(1998)253 DEF 19980205; FIRST REGISRATION: EU/1/97/057/001 19980205
0164843	98C0023	Belgium		PRODUCT NAME: SAMARIUM (153 SM) LEXIDRONAM PENTASODIQUE; NAT. REGISTRATION NO/DATE: EU/1/97/057/001 19980205; FIRST REGISTRATION: CH 54265 19971006
0513917	98C0018	Netherlands		PRODUCT NAME: SAMARIUM LEXIDRONAM PENTASODIQUE; NAT. REGISTRATION NO/DATE: EU/1/97/057/001 19980205; FIRST REGISTRATION: CH - 54265 19971006
0164843	SPC/GB98/028	United Kingdom		PRODUCT NAME: 153 SAMARIUM ETHYLENEDIAMINETETRAMETHYLENEPHOSPHONIC ACID (QUADRAMET); REGISTERED: CH CH 54265 19971006; UK EU/1/97/057/001 19980205

Quadramet (Samarium-153-lexidronam) Investment Scenario: Market Dynamics and Financial Trajectory

Last updated: February 3, 2026

---

Summary

Quadramet (samarium-153-lexidronam) is a radiopharmaceutical used predominantly for palliation of pain associated with bone metastases. Despite FDA approval since 1997, its market has experienced stagnation due to competition from other therapies, regulatory shifts, and evolving healthcare policies. This report analyzes its current market landscape, growth drivers, key challenges, projected financial performance, and investment outlook.

---

1. What Is Quadramet, and How Does It Work?

Aspect	Details
Generic Name	Samarium-153-lexidronam
Mechanism of Action	Targets bone metastases via affinity for hydroxyapatite, delivering localized radiation to reduce tumor-associated pain.
FDA Approval	1997 for palliative treatment of pain in bone metastases in prostate, breast, and other cancers.
Administration	Intravenous infusion.
Treatment Regimen	Typically repeated every 4-8 weeks, based on patient response.

Key Specifications:

Specification	Details
Radioisotope	Samarium-153 (half-life: 46.3 hours)
Dosage	37 MBq/kg (1 mCi/kg) per dose
Shelf Life	Approximately 24 hours post-manufacture

2. Current Market Landscape

Aspect	Data & Trends
Market Size (2022)	Estimated at USD 50-70 million globally (source: GlobalData).
Major Markets	U.S., Europe, Japan, emerging countries.
Number of Patients	Estimated at 200,000 annually globally (specialized estimate based on reported bone metastases cases).
Key Competitors	External Beam Radiation Therapy, bisphosphonates, denosumab, other radiopharmaceuticals (e.g., radium-223).

Market Share Distribution (Estimated 2022)	Notes
Quadramet	~20-30% (declining trend)
Radium-223 (Zevalin)	~25-35% (gaining market share)
Alternative pain therapies	~30-45%
Others	<10%

3. Market Dynamics

Growth Drivers

Driver	Impact & Evidence
Demand for Pain Palliation	Rising incidence of bone metastases in advanced cancers; expected CAGR of 3-4% in palliation needs (source: CDC).
Aging Population	Increased elderly cancer patients elevate demand for palliative therapies.
Healthcare Investment in Nuclear Medicine	Expansion of nuclear medicine units globally supports radiopharmaceutical use.
Evolving Regulatory Environment	Pathways for accelerated approval and reimbursement in select markets bolster market access.

Key Challenges

Challenge	Impact & Evidence
Market Saturation & Competition	Radium-223 and newer agents are capturing market share; Quadramet faces obsolescence risks.
Limited Market Expansion	U.S. and Europe nearing treatment saturation; limited indications for expansion.
Reimbursement Risks	Payer hesitance due to high costs and variable clinical efficacy data.
Manufacturing Constraints	Short half-life imposes logistic barriers, affecting supply chain reliability.

4. Regulatory and Policy Factors

Aspect	Implications
FDA and EMA Approvals	Established for pain palliation, with minimal recent updates.
Reimbursement Policies	Paid through Medicare/Medicaid in U.S.; insurances in Europe follow national guidelines.
Investigational Uses	Limited; primary use remains palliation. No recent broadening of indications.
Supply Chain Regulations	Stringent radiopharmaceutical handling and disposal rules impact logistical costs.

5. Financial Trajectory and Investment Outlook

Historical Revenue Trends

Year	Estimated Revenue (USD millions)	Notes
2018	70	Peak due to established use
2019	60	Slight decline, market saturation
2020	55	Impact of COVID-19 disruptions
2021	50	Continued decline, increased competition
2022	50-70	Stabilization or slight uptick in specific markets

Forecast (2023-2028)

Year	Projected Revenue (USD millions)	Growth Rate	Assumptions
2023	52	+4%	Market stabilization; gradual uptake in non-U.S. markets
2024	55	+6%	Increased penetration in Asia & Latin America
2025	58	+5%	Slight rebound due to market expansion efforts
2026	61	+5%	Adoption in new indications or combination therapies
2027	64	+4.9%	Patent protection expiring; increased competition
2028	66	+3.1%	Market maturity; plateauing

Note: These projections are contingent upon continued market penetration, regulatory stability, and demonstration of clinical value relative to competitors.

6. Investment Risks and Opportunities

Risks	Opportunities
Competitive pressure from radium-223 and emerging therapies	Strategic partnerships with healthcare providers or licensing deals
Regulatory stagnation or negative clinical data	Niche positioning in specific patient populations
Logistic challenges due to short half-life	Innovation in manufacturing, logistics, or novel delivery methods
Limited ability to expand indications	Potential repurposing or adjunctive use in combination therapies

7. Comparative Analysis: Quadramet vs. Radium-223

Parameter	Quadramet	Radium-223 (e.g., Xofigo)
Approval Year	1997	2013
Indication	Bone pain palliation	Bone metastases in castration-resistant prostate cancer
Half-life	46.3 hours	11.4 days
Delivery	IV infusion	IV infusion
Number of Doses per Treatment	Usually 1	Up to 6 doses at 4-week intervals
Market Trends	Declining	Growing in specific indications
Reimbursement	Stable but declining	Increasing, supported by clinical data

8. Strategic Recommendations for Investors

Recommendation	Rationale
Focus on niche markets and geographic expansion	Underpenetrated regions like Asia-Pacific.
Monitor regulatory developments	Any shifts enabling indication expansion or new approvals can be transformative.
Partner with specialty clinics	Establish presence in nuclear medicine centers to stabilize sales.
Invest in supply chain innovations	Overcome logistical hurdles due to radionuclide's half-life constraints.
Track competitive dynamics	Rapid advancements in radiopharmaceuticals may influence market share.

---

Key Takeaways

• Market viability for Quadramet remains primarily in palliative care, but facing significant headwinds from newer therapies and market saturation.

• Revenue prospects are modest, with forecasted CAGR of approximately 3-4% over the next five years, contingent upon geographic expansion and clinical positioning.

• Competitive landscape favors innovative agents like radium-223, which possess longer half-lives and broader approved indications.

• Investment risk is heightened by logistical challenges, patent expiries, and evolving healthcare policies, yet niche opportunities persist in underdeveloped markets.

• Strategic focus should include licensing, supply chain optimization, and exploring new combination indications to sustain or boost asset value.

---

FAQs

Q1: Why has Quadramet's market share declined since its peak?
A: Increased competition from long-half-life agents like radium-223, market saturation in existing indications, and logistical challenges in distribution have reduced its relative market share.

Q2: Are there any regulatory updates that could boost Quadramet’s market?
A: As of 2023, no significant regulatory shifts are reported. However, proposals to streamline approval for radiopharmaceuticals or expand indications could benefit the drug.

Q3: What is the current patent status of Quadramet?
A: Since its original patent expired decades ago, Quadramet operates as a generic radiopharmaceutical, limiting exclusivity advantages and exposing it to generic competition.

Q4: Which emerging markets show growth potential for Quadramet?
A: Countries in Asia-Pacific and Latin America with expanding healthcare infrastructure and increasing cancer rates represent opportunities for deployment.

Q5: How does logistical management affect investment in radiopharmaceuticals like Quadramet?
A: Short half-life impacts manufacturing, distribution, and storage costs, elevating operational complexity and investment risk, especially outside centralized nuclear medicine facilities.

---

References

1. GlobalData. “Radiopharmaceuticals Market Report,” 2022.
2. U.S. Food and Drug Administration. “Quadramet (Samarium-153-lexidronam) Summary,” 1997.
3. International Atomic Energy Agency. “Radiopharmaceuticals: Market Trends and Logistics,” 2021.
4. American Cancer Society. “Bone Metastasis and Pain Management,” 2022.
5. ClinicalTrials.gov. “Ongoing Studies on Radiopharmaceuticals,” 2023.

---

This comprehensive analysis provides clarity for stakeholders considering investments or strategic positioning related to Quadramet, emphasizing market, regulatory, and financial factors shaping its future trajectory.